Overview

A Phase Ⅱ Clinical Study of Sanhuangjingshimingwan in Wet( Neovascular)Age-related Macular Degeneration(wAMD) Subjects

Status:
Recruiting
Trial end date:
2022-06-10
Target enrollment:
Participant gender:
Summary
The study is to evaluate the efficacy and safety of Sanhuangjingshimingwan in Wet AMD.
Phase:
Phase 2
Details
Lead Sponsor:
Tasly Pharmaceutical Group Co., Ltd